HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Lowers Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Cullinan Oncology (NASDAQ:CGEM), but lowered the price target from $49 to $34.
August 11, 2023 | 5:10 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cullinan Oncology's price target has been lowered from $49 to $34 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially lead to a short-term negative sentiment among investors, despite the 'Buy' rating being maintained. However, the impact on the stock price is uncertain as the lowered target might have already been factored into the current price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100